SK287404B6 - Pseudopolymorfná forma (-)-cis-2-(2-chlórfenyl)-5,7-dihydroxy- 8[4R-(3S-hydroxy-1-metyl)piperidinyl]-4H-1-benzopyran-4- ónhydrochloridu, spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje - Google Patents

Pseudopolymorfná forma (-)-cis-2-(2-chlórfenyl)-5,7-dihydroxy- 8[4R-(3S-hydroxy-1-metyl)piperidinyl]-4H-1-benzopyran-4- ónhydrochloridu, spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje Download PDF

Info

Publication number
SK287404B6
SK287404B6 SK1036-2002A SK10362002A SK287404B6 SK 287404 B6 SK287404 B6 SK 287404B6 SK 10362002 A SK10362002 A SK 10362002A SK 287404 B6 SK287404 B6 SK 287404B6
Authority
SK
Slovakia
Prior art keywords
flavopiridol
pseudopolymorph
thick
forms
pharmaceutical composition
Prior art date
Application number
SK1036-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK10362002A3 (sk
Inventor
Gary L. Bafus
Christine M. Harrison-Bowman
Gary L. Silvey
Original Assignee
Aventis Holdings Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Holdings Inc. filed Critical Aventis Holdings Inc.
Publication of SK10362002A3 publication Critical patent/SK10362002A3/sk
Publication of SK287404B6 publication Critical patent/SK287404B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Stereophonic System (AREA)
  • Inorganic Insulating Materials (AREA)
SK1036-2002A 2000-01-18 2001-01-08 Pseudopolymorfná forma (-)-cis-2-(2-chlórfenyl)-5,7-dihydroxy- 8[4R-(3S-hydroxy-1-metyl)piperidinyl]-4H-1-benzopyran-4- ónhydrochloridu, spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje SK287404B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48471700A 2000-01-18 2000-01-18
PCT/US2001/000519 WO2001053293A1 (fr) 2000-01-18 2001-01-08 Pseudopolymorphe d'hydrochlorure (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one

Publications (2)

Publication Number Publication Date
SK10362002A3 SK10362002A3 (sk) 2003-01-09
SK287404B6 true SK287404B6 (sk) 2010-09-07

Family

ID=23925305

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1036-2002A SK287404B6 (sk) 2000-01-18 2001-01-08 Pseudopolymorfná forma (-)-cis-2-(2-chlórfenyl)-5,7-dihydroxy- 8[4R-(3S-hydroxy-1-metyl)piperidinyl]-4H-1-benzopyran-4- ónhydrochloridu, spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje

Country Status (26)

Country Link
EP (1) EP1259507B1 (fr)
JP (1) JP2003520797A (fr)
KR (1) KR100806464B1 (fr)
CN (1) CN1174977C (fr)
AT (1) ATE273303T1 (fr)
AU (1) AU2001226346A1 (fr)
BR (1) BR0107726A (fr)
CA (1) CA2397593C (fr)
CZ (1) CZ301195B6 (fr)
DE (1) DE60104822T2 (fr)
DK (1) DK1259507T3 (fr)
EA (1) EA005247B1 (fr)
ES (1) ES2222332T3 (fr)
HU (1) HUP0204126A3 (fr)
IL (2) IL150638A0 (fr)
MX (1) MXPA02007005A (fr)
NO (1) NO322572B1 (fr)
NZ (1) NZ520280A (fr)
PL (1) PL200696B1 (fr)
PT (1) PT1259507E (fr)
SI (1) SI1259507T1 (fr)
SK (1) SK287404B6 (fr)
TR (1) TR200402036T4 (fr)
TW (1) TWI284129B (fr)
WO (1) WO2001053293A1 (fr)
ZA (1) ZA200205639B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
EP4218820A3 (fr) 2017-03-16 2023-09-20 Eisai R&D Management Co., Ltd. Polythérapies pour le traitement du cancer du sein
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (fr) * 1986-04-11 1989-02-04 Hoechst India
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs

Also Published As

Publication number Publication date
ES2222332T3 (es) 2005-02-01
HUP0204126A2 (hu) 2003-04-28
PL356165A1 (en) 2004-06-14
EP1259507B1 (fr) 2004-08-11
CZ301195B6 (cs) 2009-12-02
EA005247B1 (ru) 2004-12-30
TR200402036T4 (tr) 2004-10-21
DK1259507T3 (da) 2004-11-01
PL200696B1 (pl) 2009-01-30
CA2397593C (fr) 2009-11-10
WO2001053293A1 (fr) 2001-07-26
CZ20022466A3 (cs) 2002-11-13
NO322572B1 (no) 2006-10-30
TWI284129B (en) 2007-07-21
JP2003520797A (ja) 2003-07-08
MXPA02007005A (es) 2004-09-06
PT1259507E (pt) 2004-12-31
CA2397593A1 (fr) 2001-07-26
DE60104822D1 (de) 2004-09-16
IL150638A0 (en) 2003-02-12
IL150638A (en) 2009-06-15
KR20020069361A (ko) 2002-08-30
DE60104822T2 (de) 2005-09-01
ZA200205639B (en) 2003-10-15
BR0107726A (pt) 2002-10-01
SI1259507T1 (en) 2005-02-28
SK10362002A3 (sk) 2003-01-09
KR100806464B1 (ko) 2008-02-21
AU2001226346A1 (en) 2001-07-31
NO20023386D0 (no) 2002-07-12
NO20023386L (no) 2002-09-12
HUP0204126A3 (en) 2006-02-28
NZ520280A (en) 2004-04-30
EP1259507A1 (fr) 2002-11-27
CN1174977C (zh) 2004-11-10
ATE273303T1 (de) 2004-08-15
CN1395576A (zh) 2003-02-05
EA200200775A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
KR20160003899A (ko) 마크롤리드 고체상 형태
DE69911935T3 (de) Granulatimide-derivate zur behandlung von krebs
EP0484988A1 (fr) Dérivés de 2-(1-pipérazinyl)-4-phénylcycloalkanopyrimidine et composition pharmaceutique les contenant
US6576647B2 (en) Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
JP2004513126A (ja) 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
US6821990B2 (en) Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
SK287404B6 (sk) Pseudopolymorfná forma (-)-cis-2-(2-chlórfenyl)-5,7-dihydroxy- 8[4R-(3S-hydroxy-1-metyl)piperidinyl]-4H-1-benzopyran-4- ónhydrochloridu, spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
SK287216B6 (sk) Hydrochloridová etanolová solvátová forma (-)-cis-2-(2- chlórfenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-metyl)piperidinyl]- 4H-1-benzopyran-4-ónu, spôsob jej prípravy, farmaceutická kompozícia, ktorá ju obsahuje, a jej použitie
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
TWI826013B (zh) 咪唑啉酮衍生物的晶型
CN113861184B (zh) 2-(取代的嘧啶基)噻唑甲酰胺化合物的磷酸盐及其用途
WO2022199699A1 (fr) Forme cristalline de sel de composé hétérocyclique condensé contenant de l'azote, son procédé de préparation et son utilisation
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
SK288226B6 (sk) Kryštalická alfa-forma Imatinib mezylátu s novým habitom a spôsob jeho prípravy a použitie

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: HMR PHARMA, INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: AVENTIS PHARMACEUTICALS INC., BRIDGEWATER, NJ, US

Effective date: 20100625

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: HMR PHARMA, INC., GREENVILLE, DELAWARE, US

Effective date: 20100625

PC4A Assignment and transfer of rights

Owner name: AVENTISUB II INC., GREENVILLE, DELAWARE, US

Free format text: FORMER OWNER: AVENTIS HOLDINGS INC., GREENVILLE, DELAWARE, US

Effective date: 20100303

MK4A Expiry of patent

Expiry date: 20210108